Brote ampollar en un paciente psoriásico

Contenido principal del artículo

Daniela Malieni
Mariana Guzzi Maqueda
Isabel Hidalgo Parra
Gastón Galimberti
Alicia Kowalczuk
Ricardo Galimberti

Resumen

.

Downloads

Download data is not yet available.

Detalles del artículo

Sección

Iconografía dermatológica

Cómo citar

1.
Malieni D, Guzzi Maqueda M, Hidalgo Parra I, Galimberti G, Kowalczuk A, Galimberti R. Brote ampollar en un paciente psoriásico. Rev Hosp Ital B.Aires [Internet]. 2006 Oct. 10 [cited 2026 Jun. 6];26(3):114-6. Available from: https://ojs.hospitalitaliano.org.ar/index.php/revistahi/article/view/1148

Referencias

Yancey KB, Egan CA. Pemphigoid: clinical,histologic, immunopathologic, and therapeuticconsiderations. JAMA 2000;284(3):350-6. DOI: https://doi.org/10.1001/jama.284.3.350

Mutasim DF, Bilic M, Hawayek LH, et al.Immunobullous diseases. J Am Acad Dermatol2005;52(6):1029-43. DOI: https://doi.org/10.1016/j.jaad.2004.11.064

McKenna JK, Leiferman KM. Dermatologicdrug reactions. Immunol Allergy Clin North Am2004;24(3):399-423, vi. DOI: https://doi.org/10.1016/j.iac.2004.03.007

Smith EP, Taylor TB, Meyer LJ, et al. Antigenidentification in drug-induced bullouspemphigoid. J Am Acad Dermatol 1993;29(5Pt 2):879-82. DOI: https://doi.org/10.1016/0190-9622(93)70262-R

Lee JJ, Downham TF 2nd. Furosemide-induced bullous pemphigoid: case report andreview of literature. J Drugs Dermatol 2006;5(6):562-4.

Wojnarowska F, Kirtschig G, Highet AS,et al. Guidelines for the management ofbullous pemphigoid. Br J Dermatol 2002;147(2):214-21. DOI: https://doi.org/10.1046/j.1365-2133.2002.04835.x

Joly P, Roujeau JC, Benichou J, et al. Acomparison of oral and topical corticosteroidsin patients with bullous pemphigoid. N Engl JMed 2002;346(5):321-7. DOI: https://doi.org/10.1056/NEJMoa011592

Ahmed AR. Intravenous immunoglobulintherapy for patients with bullous pemphigoidunresponsive to conventionalimmunosuppressive treatment. J Am AcadDermatol 2001;45(6):825-35 DOI: https://doi.org/10.1067/mjd.2001.116337

Leonardi CL. Efalizumab: an overview. J AmAcad Dermatol 200349(2 Suppl):S98-104 DOI: https://doi.org/10.1016/S0190-9622(03)01141-1

Artículos más leídos del mismo autor/a

1 2 > >>